SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is generating significant community buzz, with conversation centering on its robust utility as an AI agent token and recent major exchange listings. Enthusiasm is high for its potential within the Coinbase Base ecosystem, leading many to advocate for buying dips amidst some concern over its inherent volatility.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN CRYPTO is trending as its community actively builds momentum for the upcoming 4/20 cultural event, fueled by ongoing discussions around cannabis rescheduling and its vision as a "Bitcoin but way higher" token for long-term holders.

Frontier Group Holdings, Inc. engages in the provision of air transportation. The company was founded on July 5, 1994 and is headquartered in Denver, CO.

Frontier Group Holdings Inc

Frontier Group Holdings is trending as investors weigh the implications of competitor Spirit Airlines' recent second bankruptcy filing, with many anticipating ULCC will gain market share. This key development, alongside a recent CEO transition, fuels community debate regarding the future profitability and strategic positioning of ultra-low-cost carriers within the volatile airline industry.

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.

SpyGlass Pharma Inc.

SpyGlass Pharma (SGP) is trending with a surge in community interest and watchlist placements, as investors eagerly anticipate a potential move, fueled by recent analytical content circulating online.

Align Technology, Inc. is a medical device company, which engages in the design, manufacture, and market of orthodontics, restorative, and aesthetic dentistry products. It operates through the Clear Aligner and Systems and Services segments. The Clear Aligner segment consists of invisalign full, teen, and assist products, and Vivera retainers for treating malocclusion. The Systems and Services segment includes sales related to iTero intraoral scanning systems, which includes a single hardware platform and restorative or orthodontic software options, upgrades and leases of scanner systems, sales of pre-owned scanner systems, subscription software, disposables, pay per scan services, as well as exocad’s CAD/CAM software solutions that integrate workflows to dental labs and dental practices. The company was founded by Zia Chishti, Brian Freyburger, and Kelsey Wirth in March 1997 and is headquartered in Tempe, AZ.

Align Technology, Inc.

Align Technology is trending due to its strong recent Q4 earnings beat, which highlighted robust Clear Aligner volume and prompted multiple analyst target price upgrades. The community is actively discussing the potential for a significant re-pricing, buoyed by the company's strong cash position and ongoing share buyback program.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB Construction Holdings is gaining significant attention following news of a substantial private placement, which many in the community interpret as a strong capital infusion to drive growth and execute on its expanding pipeline of construction contracts. This development has fueled strong bullish momentum and new highs, with investors actively debating potential dilution from the offering amidst the stock's low float and recent volatility.

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through the company's two core offerings, Canopy and Horizon. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Ginkgo Bioworks is trending after its collaboration with OpenAI to develop an AI-driven autonomous lab demonstrated significant cost reductions in protein synthesis. This development is fueling community discussions around the company's potential for improved profitability, strategic re-rating, and its role in U.S. biomanufacturing initiatives driven by AI and robotics.

WorldFinancial

World Liberty Financial (WLFI) is trending due to ongoing congressional scrutiny over a significant foreign investment deal and its pursuit of a national trust banking license, sparking debate about transparency and political influence in the crypto space. The community remains sharply divided, with advocates championing WLFI's potential to revolutionize finance through its USD1 stablecoin and upcoming real-world asset tokenization, while detractors view it as a politically-linked "scam."

Cooper-Standard Holdings, Inc. engages in the manufacture of sealing and fluid handling systems, including fuel and brake delivery and fluid transfer systems. It operates through the following segments: Sealing Systems, Fluid Handling Systems, and Corporate, Eliminations and Other. The Sealing Systems segment consists of manufacturing products for interior vehicle protection, dust and noise intrusion. The Fluid Handling Systems segment includes products that help convey, connect, control, and communicate throughout the fluid systems. The Corporate, Eliminations and Other segment is for all other business activities. The company was founded in 2004 and is headquartered in Northville, MI.

Cooper-Standard Holdings Inc

Cooper-Standard Holdings is trending as Stifel reiterated its Buy rating and raised price targets, citing confidence in the company's differentiated growth and margin expansion driven by new platform wins and increased hybrid/EV content. The community is actively debating its long-term potential and undervalued status amidst its debt reduction efforts, though some voice concerns over price volatility and perceived market manipulation.

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Savara Inc

Savara Inc. is trending due to highly positive Phase 3 clinical trial results for Molgramostim in autoimmune Pulmonary Alveolar Proteinosis, a rare lung disease with no approved therapies, which has led to significant analyst price target raises and robust community discussion around impending FDA approval and potential M&A.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beneficient (BENF) Expected to Announce Quarterly Earnings on Thursday

Beneficient (NASDAQ:BENF) will be releasing its Q3 2026 earnings before the market opens on Thursday, February 12. (View Earnings Report at...

Beneficient (NASDAQ:BENF) Short Interest Update

Beneficient (NASDAQ:BENF - Get Free Report) was the target of a large decrease in short interest in the month of January. As of January 15th, there was short interest totaling 107,656 shares, a...

Beneficient (NASDAQ:BENF) Shares Up 2.6% - Still a Buy?

Beneficient (NASDAQ:BENF) Stock Price Up 2.6% - Time to Buy...

Short Interest in Beneficient (NASDAQ:BENF) Grows By 84.8%

Beneficient (NASDAQ:BENF - Get Free Report) was the target of a large growth in short interest in December. As of December 31st, there was short interest totaling 139,093 shares, a growth of 84.8...

What Does the Market Think About Beneficient?

Beneficient

BENF: F1Q26 Earnings - EPS Miss on Higher Expenses and Lower Shares Outstanding

Beneficient is a financial services company, which engages in providing alternative assets, financial and investment services. It offers services to individual investors, wealth advisors, general partners, and institutional investors. It operates through the following segments: Ben Liquidity, Ben Custody, Customer ExAlt Trusts, and Corporate and Other. The Ben Liquidity segment offers liquidity products and services. The Ben Custody segment provides trust and custody administration services. The Customer ExAlt Trusts segment includes investments in alternative assets. The Corporate and Other segment relates to its overhead and administrative costs. The company was founded by Brad K. Heppner on June 6, 2023 and is headquartered in Dallas, TX.

Beneficient - Ordinary Shares - Class A

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

Current Price	$4.41
Prev Close	$4.31
Open	$4.33
Dividend Yield	0.00%
50-Day Moving Average	$5.44
Beta	0.31
Avg. Volume	53,468.00
PE Ratio	-0.05

52-Week High	$12.48
52-Week Low	$1.75
Market Capitalization	$62.39M
EPS (Annual)	$0.516
Price to Book	-0.02
Revenue Per Employee	$14,527.27
Enterprise Value/EBITDA	N/A

BENF
Beneficient - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BENF News

BENFBeneficient - Ordinary Shares - Class A